Alkem launches Kojiglo serum to manage facial hyperpigmentation
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
EBITDA rose to Rs. 14.8 crore, marking a 16.5% y-o-y increase, while net profit surged to Rs. 6.4 crore
It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Subscribe To Our Newsletter & Stay Updated